1
|
Yanaba K, Bouaziz JD, Matsushita T, Magro
CM, St Clair EW and Tedder TF: B-lymphocyte contributions to human
autoimmune disease. Immunol Rev. 223:284–299. 2008. View Article : Google Scholar : PubMed/NCBI
|
2
|
Mak A and Kow N: The pathology of T cells
in systemic lupus erythematosus. J Immunol Res. 2014:4190292014.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Celhar T, Magalhães R and Fairhurst AM:
TLR7 and TLR9 in SLE: When sensing self goes wrong. Immunol Res.
53:58–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kunz M: Lupus erythematosus. Part I:
Epidemiology, genetics and immunology. J Dtsch Dermatol Ges.
11:709–719; quiz 720, 709–720; quiz 721. 2013.[(In English,
German)]. View Article : Google Scholar : PubMed/NCBI
|
5
|
Davis LS, Hutcheson J and Mohan C: The
role of cytokines in the pathogenesis and treatment of systemic
lupus erythematosus. J Interferon Cytokine Res. 31:781–789. 2011.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Ramji DP and Foka P:
CCAAT/enhancer-binding proteins: Structure, function and
regulation. Biochem J. 365:561–575. 2002. View Article : Google Scholar : PubMed/NCBI
|
7
|
Sears RC and Sealy L: Multiple forms of
C/EBP beta bind the EFII enhancer sequence in the Rous sarcoma
virus long terminal repeat. Mol Cell Biol. 14:4855–4871. 1994.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Yamanaka R, Lekstrom-Himes J, Barlow C,
Wynshaw-Boris A and Xanthopoulos KG: CCAAT/enhancer binding
proteins are critical components of the transcriptional regulation
of hematopoiesis (Review). Int J Mol Med. 1:213–221.
1998.PubMed/NCBI
|
9
|
Li-Weber M, Salgame P, Hu C, Davydov IV
and Krammer PH: Differential interaction of nuclear factors with
the PRE-I enhancer element of the human IL-4 promoter in different
T cell subsets. J Immunol. 158:1194–1200. 1997.PubMed/NCBI
|
10
|
Huber R, Pietsch D, Panterodt T and Brand
K: Regulation of C/EBPβ and resulting functions in cells of the
monocytic lineage. Cell Signal. 24:1287–1296. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lane MD, Tang QQ and Jiang MS: Role of the
CCAAT enhancer binding proteins (C/EBPs) in adipocyte
differentiation. Biochem Biophys Res Commun. 266:677–683. 1999.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Zahnow CA: CCAAT/enhancer-binding protein
beta: Its role in breast cancer and associations with receptor
tyrosine kinases. Expert Rev Mol Med. 11:e122009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Fausto N: Liver regeneration. J Hepatol.
32(1): Suppl. S19–S31. 2000. View Article : Google Scholar
|
14
|
Tengku-Muhammad TS, Hughes TR, Ranki H,
Cryer A and Ramji DP: Differential regulation of macrophage
CCAAT-enhancer binding protein isoforms by lipopolysaccharide and
cytokines. Cytokine. 12:1430–1436. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Natsuka S, Akira S, Nishio Y, Hashimoto S,
Sugita T, Isshiki H and Kishimoto T: Macrophage
differentiation-specific expression of NF-IL6, a transcription
factor for interleukin-6. Blood. 79:460–466. 1992.PubMed/NCBI
|
16
|
Nolan A, Weiden MD, Thurston G and Gold
JA: Vascular endothelial growth factor blockade reduces plasma
cytokines in a murine model of polymicrobial sepsis. Inflammation.
28:271–278. 2004. View Article : Google Scholar : PubMed/NCBI
|
17
|
Peng H, Wang W, Zhou M, Li R, Pan HF and
Ye DQ: Role of interleukin-10 and interleukin-10 receptor in
systemic lupus erythematosus. Clin Rheumatol. 32:1255–1266. 2013.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Yap DY and Lai KN: The role of cytokines
in the pathogenesis of systemic lupus erythematosus-from bench to
bedside. Nephrology (Carlton). 18:243–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Fojtíková M, Cerná M and Pavelka K: A
review of the effects of prolactin hormone and cytokine on the
development and pathogenesis of autoimmune diseases. Vnitr Lek.
56:402–413. 2010.(In Czech). PubMed/NCBI
|
20
|
Cigni A, Pileri PV, Faedda R, Gallo P,
Sini A, Satta AE, Marras R, Carta E, Argiolas D, Rum I and Masala
A: Interleukin 1, interleukin 6, interleukin 10, and tumor Necrosis
factor α in active and quiescent systemic lupus erythematosus. J
Investig Med. 62:825–829. 2014. View Article : Google Scholar : PubMed/NCBI
|
21
|
Lyn-Cook BD, Xie C, Oates J, Treadwell E,
Word B, Hammons G and Wiley K: Increased expression of Toll-like
receptors (TLRs) 7 and 9 and other cytokines in systemic lupus
erythematosus (SLE) patients: Ethnic differences and potential new
targets for therapeutic drugs. Mol Immunol. 61:38–43. 2014.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhou L, Lu G, Shen L, Wang L and Wang M:
Serum levels of three angiogenic factors in systemic lupus
erythematosus and their clinical significance. Biomed Res Int.
2014:6271262014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ma A and Malynn BA: A20: Linking a complex
regulator of ubiquitylation to immunity and human disease. Nat Rev
Immunol. 12:774–785. 2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Lai TY, Wu SD, Tsai MH, Chuang EY, Chuang
LL, Hsu LC and Lai LC: Transcription of Tnfaip3 is regulated by
NF-κB and p38 via C/EBPβ in activated macrophages. PLoS One.
8:e731532013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Gateva V, Sandling JK, Hom G, Taylor KE,
Chung SA, Sun X, Ortmann W, Kosoy R, Ferreira RC, Nordmark G, et
al: A large-scale replication study identifies TNIP1, PRDM1, JAZF1,
UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.
Nat Genet. 41:1228–1233. 2009. View
Article : Google Scholar : PubMed/NCBI
|
26
|
Zhou J, Wu R, High AA, Slaughter CA,
Finkelstein D, Rehg JE, Redecke V and Häcker H: A20-binding
inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated
CCAAT/enhancer-binding protein β activation and protects from
inflammatory disease. Proc Natl Acad Sci USA. 108:E998–E1006. 2011.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Tan EM, Cohen AS, Fries JF, Masi AT,
McShane DJ, Rothfield NF, Schaller JG, Talal N and Winchester RJ:
The 1982 revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum. 25:1271–1277. 1982. View Article : Google Scholar : PubMed/NCBI
|
28
|
Gladman DD, Ibanez D and Urowitz MB:
Systemic lupus erythematosus disease activity index 2000. J
Rheumatol. 29:288–291. 2002.PubMed/NCBI
|
29
|
Wrone DA and Kwon NJ: Andrews' diseases of
the skin: Clinical dermatology. Archives of Dermatology. 137:518.
2001.
|
30
|
O'Neill LA, Bryant CE and Doyle SL:
Therapeutic targeting of Toll-like receptors for infectious and
inflammatory diseases and cancer. Pharmacol Rev. 61:177–197. 2009.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Kawai T, Adachi O, Ogawa T, Takeda K and
Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin.
Immunity. 11:115–122. 1999. View Article : Google Scholar : PubMed/NCBI
|
32
|
Häcker H, Vabulas RM, Takeuchi O, Hoshino
K, Akira S and Wagner H: Immune cell activation by bacterial
CpG-DNA through myeloid differentiation marker 88 and tumor
necrosis factor receptor-associated factor (TRAF)6. J Exp Med.
192:595–600. 2000. View Article : Google Scholar : PubMed/NCBI
|
33
|
Häcker H, Redecke V, Blagoev B,
Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Häcker
G, et al: Specificity in Toll-like receptor signalling through
distinct effector functions of TRAF3 and TRAF6. Nature.
439:204–207. 2006. View Article : Google Scholar : PubMed/NCBI
|
34
|
Horie R, Ishida T, Maruyama-Nagai M, Ito
K, Watanabe M, Yoneyama A, Higashihara M, Kimura S and Watanabe T:
TRAF activation of C/EBPbeta (NF-IL6) via p38 MAPK induces HIV-1
gene expression in monocytes/macrophages. Microbes Infect.
9:721–728. 2007. View Article : Google Scholar : PubMed/NCBI
|
35
|
Takeuchi O and Akira S: Pattern
recognition receptors and inflammation. Cell. 140:805–820. 2010.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu
Z, Xu JH, Cai ZM, Huang W, Zhao GP, et al: Genome-wide association
study in a Chinese Han population identifies nine new
susceptibility loci for systemic lupus erythematosus. Nat Genet.
41:1234–1237. 2009. View
Article : Google Scholar : PubMed/NCBI
|
37
|
Düwel M, Welteke V, Oeckinghaus A, Baens
M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P and Krappmann D:
A20 negatively regulates T cell receptor signaling to NF-kappaB by
cleaving Malt1 ubiquitin chains. J Immunol. 182:7718–7728. 2009.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Li D, Wang L, Fan Y, Song L, Guo C, Zhu F,
Zhang L and Shi Y: Down-regulation of A20 mRNA expression in
peripheral blood mononuclear cells from patients with systemic
lupus erythematosus. J Clin Immunol. 32:1287–1291. 2012. View Article : Google Scholar : PubMed/NCBI
|
39
|
Zhang DM, Cheng LQ, Zhai ZF, Feng L, Zhong
BY, You Y, Zhang N, Song ZQ, Yang XC, Chen FR and Hao F:
Single-nucleotide polymorphism and haplotypes of TNIP1 associated
with systemic lupus erythematosus in a Chinese Han population. J
Rheumatol. 40:1535–1544. 2013. View Article : Google Scholar : PubMed/NCBI
|
40
|
Mele A, Cervantes JR, Chien V, Friedman D
and Ferran C: Single nucleotide polymorphisms at the TNFAIP3/A20
locus and susceptibility/resistance to inflammatory and autoimmune
diseases. Adv Exp Med Biol. 809:163–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
41
|
Musone SL, Taylor KE, Lu TT, Nititham J,
Ferreira RC, Ortmann W, Shifrin N, Petri MA, Kamboh MI, Manzi S, et
al: Multiple polymorphisms in the TNFAIP3 region are independently
associated with systemic lupus erythematosus. Nat Genet.
40:1062–1064. 2008. View
Article : Google Scholar : PubMed/NCBI
|
42
|
Yildirim-Toruner C and Diamond B: Current
and novel therapeutics in the treatment of systemic lupus
erythematosus. J Allergy Clin Immunol. 127:303–312; quiz 313–314.
2011. View Article : Google Scholar : PubMed/NCBI
|
43
|
Sriskantharajah S and Ley SC: Cell
biology. Turning off inflammation signaling. Science.
327:1093–1094. 2010. View Article : Google Scholar : PubMed/NCBI
|
44
|
Aringer M and Smolen JS: TNF inhibition in
SLE: Where do we stand? Lupus. 18:5–8. 2009. View Article : Google Scholar : PubMed/NCBI
|